Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson’s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study

BACKGROUND: Levodopa remains the most effective symptomatic treatment for Parkinson’s disease (PD) more than 50 years after its clinical introduction. However, the onset of motor complications can limit pharmacological intervention with levodopa, which can be a challenge when treating PD patients. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatano, Taku, Kano, Osamu, Sengoku, Renpei, Yoritaka, Asako, Suzuki, Keisuke, Nishikawa, Noriko, Mukai, Yohei, Nomura, Kyoichi, Yoshida, Norihito, Seki, Morinobu, Matsukawa, Miho Kawabe, Terashi, Hiroo, Kimura, Katsuo, Tashiro, Jun, Hirano, Shigeki, Murakami, Hidetomo, Joki, Hideto, Uchiyama, Tsuyoshi, Shimura, Hideki, Ogaki, Kotaro, Fukae, Jiro, Tsuboi, Yoshio, Takahashi, Kazushi, Yamamoto, Toshimasa, Yanagisawa, Naotake, Nagayama, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892732/
https://www.ncbi.nlm.nih.gov/pubmed/35241003
http://dx.doi.org/10.1186/s12883-022-02600-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892732/
https://www.ncbi.nlm.nih.gov/pubmed/35241003
http://dx.doi.org/10.1186/s12883-022-02600-w

Ejemplares similares